DK1597359T3 - Vaccine af inaktiveret nodavirus - Google Patents

Vaccine af inaktiveret nodavirus

Info

Publication number
DK1597359T3
DK1597359T3 DK04712006T DK04712006T DK1597359T3 DK 1597359 T3 DK1597359 T3 DK 1597359T3 DK 04712006 T DK04712006 T DK 04712006T DK 04712006 T DK04712006 T DK 04712006T DK 1597359 T3 DK1597359 T3 DK 1597359T3
Authority
DK
Denmark
Prior art keywords
vaccine
nodavirus
inactivated
inactivated nodavirus
fish
Prior art date
Application number
DK04712006T
Other languages
English (en)
Inventor
Santos Nuno Dos
Jacqueline Ireland
Andrew Cartner Barnes
Michael Horne
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32910468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1597359(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0303867A external-priority patent/GB0303867D0/en
Priority claimed from GB0320195A external-priority patent/GB0320195D0/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1597359T3 publication Critical patent/DK1597359T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30061—Methods of inactivation or attenuation
    • C12N2770/30063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)
DK04712006T 2003-02-19 2004-02-18 Vaccine af inaktiveret nodavirus DK1597359T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0303867A GB0303867D0 (en) 2003-02-19 2003-02-19 Organic compounds
GB0320195A GB0320195D0 (en) 2003-08-28 2003-08-28 Organic compounds
PCT/EP2004/001543 WO2004074467A1 (en) 2003-02-19 2004-02-18 Inactivated nodavirus vaccine

Publications (1)

Publication Number Publication Date
DK1597359T3 true DK1597359T3 (da) 2009-11-16

Family

ID=32910468

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04712006T DK1597359T3 (da) 2003-02-19 2004-02-18 Vaccine af inaktiveret nodavirus

Country Status (18)

Country Link
US (2) US20060257425A1 (da)
EP (1) EP1597359B1 (da)
JP (1) JP4664901B2 (da)
AT (1) ATE437224T1 (da)
AU (1) AU2004213566B2 (da)
CA (1) CA2512930C (da)
CL (1) CL2004000282A1 (da)
CY (1) CY1109344T1 (da)
DE (1) DE602004022139D1 (da)
DK (1) DK1597359T3 (da)
ES (1) ES2328141T3 (da)
HK (1) HK1085765A1 (da)
MY (1) MY143785A (da)
NO (1) NO336878B1 (da)
PT (1) PT1597359E (da)
SI (1) SI1597359T1 (da)
TW (1) TWI347364B (da)
WO (1) WO2004074467A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003262A1 (es) * 2007-11-02 2009-06-26 Intervet Int Bv Vacuna que comprende lactococcus garviae, pasteurella piscicida, vibrio anguillarum y nocardia seriolae; y uso de dichas bacterias para combatir infecciones de nocardia en peces.
KR101608121B1 (ko) * 2012-09-20 2016-04-01 중앙대학교 산학협력단 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
KR101414009B1 (ko) * 2012-11-16 2014-07-02 주식회사 젠닥스 형질전환 식물체를 이용한 어류 바이러스성 신경괴사증 예방 경구백신 제조방법과 그에 따른 식물체
EP3003364B1 (en) * 2013-05-28 2020-11-04 Elanco Tiergesundheit AG Interactions of betanodaviruses in infection
ES2795040T3 (es) 2016-02-02 2020-11-20 Benchmark Animal Health Ltd Métodos para producir virus
CN113429338B (zh) * 2021-05-20 2023-05-02 陕西泰合利华工业有限公司 一种合成氟吡菌酰胺的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
CA2324478C (en) * 1998-03-31 2011-08-23 University Of Maryland Biotechnology Institute A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts
US20040001863A1 (en) * 1998-12-03 2004-01-01 Shau-Chi Chi Immortal cell line derived from grouper Epinephelus coioides and its applications therein
TWI220904B (en) * 1998-12-03 2004-09-11 Nat Science Council An immortal cell line derived from grouper Epinephelus coioides and its applications therein
JP2001161355A (ja) * 1999-11-25 2001-06-19 Natl Sci Council ハタ科チャイロマルハタから得られる不死の細胞株およびその応用
WO2003050142A1 (en) * 2001-12-07 2003-06-19 Schweitzer Chemical Corporation Usa Vaccines and antibodies produced from viruses derived from an immortal cell line of grouper epinephelus coioides
US20050118194A1 (en) * 2003-12-01 2005-06-02 Sin Yoke M. Oral vaccine, method for its preparation and use thereof

Also Published As

Publication number Publication date
JP2006517943A (ja) 2006-08-03
ATE437224T1 (de) 2009-08-15
AU2004213566A1 (en) 2004-09-02
US20060257425A1 (en) 2006-11-16
ES2328141T3 (es) 2009-11-10
SI1597359T1 (sl) 2009-12-31
WO2004074467A1 (en) 2004-09-02
TW200425899A (en) 2004-12-01
TWI347364B (en) 2011-08-21
EP1597359B1 (en) 2009-07-22
CA2512930C (en) 2015-06-02
CY1109344T1 (el) 2014-07-02
AU2004213566B2 (en) 2007-08-23
NO336878B1 (no) 2015-11-23
CA2512930A1 (en) 2004-09-02
NO20054219D0 (no) 2005-09-12
US8124100B2 (en) 2012-02-28
HK1085765A1 (en) 2006-09-01
JP4664901B2 (ja) 2011-04-06
MY143785A (en) 2011-07-15
NO20054219L (no) 2005-09-12
CL2004000282A1 (es) 2005-03-28
PT1597359E (pt) 2009-08-06
EP1597359A1 (en) 2005-11-23
US20090288179A1 (en) 2009-11-19
DE602004022139D1 (da) 2009-09-03

Similar Documents

Publication Publication Date Title
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
CY1109344T1 (el) Εμβολιο αδρανοποιημενου nodavirus
EA200700243A1 (ru) Способы лечения гепатита с
NO20070751L (no) Inhibitorer av HCV-replifikasjon
EA200701204A1 (ru) Калиевая соль ингибитора вич-интегразы
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
ATE474827T1 (de) Hcv-replikationshemmer
TW200730476A (en) N-(5-membered aromatic ring)-amido anti-viral compounds
CY1115594T1 (el) Αναστολεις του ιου της ηπατιτιδας c
DK1940786T3 (da) Biphenylderivater og deres anvendelse ved behandling af hepatitis C
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
UY27909A1 (es) Composicion herbicida
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
EA201270275A1 (ru) Кристаллическое соединение пиридазина
DK1387681T3 (da) Anvendelse af castanosperinderivater til behandling af hepatitis C
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
WO2007067517A3 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
DE69936337D1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DK1572233T3 (da) Anvendelse af HPV16 og HPV18 som vaccine mod et eller flere onkogene HPV-vira af typerne 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с